Thrombophilia as a Risk Factor for Outcome in Sepsis

  • J. -J. Hofstra
  • M. Schouten
  • M. Levi
Conference paper


Virtually all patients with sepsis have coagulation abnormalities. These abnormalities range from subtle activation of the coagulation system that can only be detected by sensitive markers for coagulation factor activation, to somewhat stronger coagulation activation detectable by a small decrease in platelet count and sub-clinical prolongation of global clotting times, to fulminant disseminated intravascular coagulation (DIC), which is characterized by simultaneous widespread microvascular thrombosis and profuse bleeding from various sites [1]. Septic patients with severe forms of DIC may present with manifest thromboembolic disease or clinically less apparent microvascular fibrin deposition, which predominantly presents as multiple organ dysfunction [2, 3, 4, 5]. Clinically relevant coagulation abnormalities are present in 50–70% of patients with severe infection or sepsis, whereas about 35% of patients will actually meet the criteria for DIC [1, 6].


Severe Sepsis Disseminate Intravascular Coag Disseminate Intravascular Coagulation Meningococcal Disease Drotrecogin Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levi M (2004) Current understanding of disseminated intravascular coagulation. Br J Haematol 124:567–576PubMedCrossRefGoogle Scholar
  2. 2.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586–592PubMedCrossRefGoogle Scholar
  3. 3.
    Colman RW, Robboy SJ, Minna JD (1979) Disseminated intravascular coagulation: a reappraisal. Annu Rev Med 30:359–374PubMedCrossRefGoogle Scholar
  4. 4.
    Levi M, van Gorp E, ten Cate H (2002) Disseminated intravascular coagulation. In: Handin R I, Lux S E, Stossel T P (eds) Blood: Principles and Practice of Hematology. JB Lippincott, Philadelphia, pp 1275–1302Google Scholar
  5. 5.
    Levi M, Marder VJ (2006) Coagulation abnormalities in sepsis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ (eds) Hemostasis and Thrombosis: Basic principles and Clinical. Practice Lippincott William and Wilkins, Philadelphia, pp 1601–1613Google Scholar
  6. 6.
    Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340:207–214.PubMedCrossRefGoogle Scholar
  7. 7.
    Levi M, Keller TT, van Gorp E, ten Cate H (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60:26–39.PubMedCrossRefGoogle Scholar
  8. 8.
    Robboy SJ, Major MC, Colman RW, Minna JD (1972) Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Human Pathology 3:327–343.PubMedCrossRefGoogle Scholar
  9. 9.
    Shimamura K, Oka K, Nakazawa M, Kojima M (1983) Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Path Lab Med 107:543–547PubMedGoogle Scholar
  10. 10.
    Coalson JJ (1986) Pathology of sepsis, septic shock, and multiple organ failure. In: Sibbald WJ (ed) Perspective on Sepsis and Septic Shock. Society of Critical Care Medicine, Fullerton, pp 27–59Google Scholar
  11. 11.
    Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91: 2850–2856PubMedCrossRefGoogle Scholar
  12. 12.
    Kessler CM, Tang Z, Jacobs HM, Szymanski LM (1997) The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 89:4393–4401PubMedGoogle Scholar
  13. 13.
    Taylor FBJ, Chang A, Ruf W, et al (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127–134PubMedGoogle Scholar
  14. 14.
    Taylor FBJ, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918–925PubMedCrossRefGoogle Scholar
  15. 15.
    Welty-Wolf KE, Carraway MS, Miller DL, et al (2001) Coagulation blockade prevents sepsisinduced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164:1988–1996PubMedGoogle Scholar
  16. 16.
    Miller DL, Welty-Wolf K, Carraway MS, et al (2002) Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 26:650–658PubMedGoogle Scholar
  17. 17.
    Fourrier F, Chopin C, Goudemand J, et al (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedCrossRefGoogle Scholar
  18. 18.
    Dhainaut JF, Yan SB, Joyce DE, et al (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2:1924–1933PubMedCrossRefGoogle Scholar
  19. 19.
    Inbal A, Kenet G, Zivelin A, et al (1997) Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 77:1086–1089PubMedGoogle Scholar
  20. 20.
    Dogan Y, Aygun D, Yilmaz Y, et al (2003) Severe protein S deficiency associated with heterozygous factor V Leiden mutation in a child with purpura fulminans. Pediatr Hematol Oncol 20:1–5PubMedCrossRefGoogle Scholar
  21. 21.
    al Ismail S, Collins P, Najib R, James-Ellison M, O’Hagan M (1999) Postinfection purpura fulminans in a patient heterozygous for prothrombin G20210A and acquired protein S resistance. Pediatr Hematol Oncol 16:561–564Google Scholar
  22. 22.
    Woods CR, Johnson CA (1998) Varicella purpura fulminans associated with heterozygosity for factor V leiden and transient protein S deficiency. Pediatrics 102:1208–1210PubMedCrossRefGoogle Scholar
  23. 23.
    Sackesen C, Secmeer G, Gurgey A, et al (1998) Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans. Pediatr Infect Dis J 17:87PubMedGoogle Scholar
  24. 24.
    Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP (2004) Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 32:S313–S319PubMedCrossRefGoogle Scholar
  25. 25.
    Levi M, de Jonge E, van der Poll T (2001) Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 29(Suppl 7):S90–94PubMedCrossRefGoogle Scholar
  26. 26.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  27. 27.
    Lay AJ, Liang Z, Rosen ED, Castellino FJ (2005) Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest 115:1552–1561PubMedCrossRefGoogle Scholar
  28. 28.
    Jalbert LR, Rosen ED, Moons L, et al (1998) Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 102:1481–1488PubMedCrossRefGoogle Scholar
  29. 29.
    Levi M, Dorffler-Melly J, Reitsma PH, et al (2003) Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 101:4823–4827PubMedCrossRefGoogle Scholar
  30. 30.
    Levi M, van der Poll T, Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109:2698–2704PubMedCrossRefGoogle Scholar
  31. 31.
    Lay AJ, Donahue D, Tsai MJ, Castellino FJ (2007) Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 109:1984–1991PubMedCrossRefGoogle Scholar
  32. 32.
    Ganopolsky JG, Castellino FJ (2004) A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 165:1433–1446PubMedGoogle Scholar
  33. 33.
    Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881–886PubMedGoogle Scholar
  34. 34.
    Minnema MC, Chang AC, Jansen PM, et al (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95:1117–1123PubMedGoogle Scholar
  35. 35.
    Yanada M, Kojima T, Ishiguro K, et al (2002) Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 99:2455–2458PubMedCrossRefGoogle Scholar
  36. 36.
    Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M (1999) Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 18: 893–896PubMedCrossRefGoogle Scholar
  37. 37.
    Kerlin BA, Yan SB, Isermann BH, et al (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102: 3085–3092PubMedCrossRefGoogle Scholar
  38. 38.
    Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA (2006) Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 34: 2201–2206PubMedCrossRefGoogle Scholar
  39. 39.
    Bernard GR, Margolis BD, Shanies HM, et al (2004) Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125: 2206–2216PubMedCrossRefGoogle Scholar
  40. 40.
    Yan SB, Nelson DR (2004) Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 32: S239–S246PubMedCrossRefGoogle Scholar
  41. 41.
    Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A (2005) Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 192:1851–1857PubMedCrossRefGoogle Scholar
  42. 42.
    Weiler H, Kerlin B, Lytle MC (2004) Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 32: S233–S238PubMedCrossRefGoogle Scholar
  43. 43.
    van der Poll T, Levi M, Buller HR, et al (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174: 729–732PubMedCrossRefGoogle Scholar
  44. 44.
    Biemond BJ, Levi M, ten Cate H, et al (1995) Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Colch) 88: 587–594Google Scholar
  45. 45.
    Yamamoto K, Loskutoff DJ (1996) Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 97: 2440–2451PubMedCrossRefGoogle Scholar
  46. 46.
    Pinsky DJ, Liao H, Lawson CA, et al (1998) Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102: 919–928PubMedCrossRefGoogle Scholar
  47. 47.
    Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M (2003) Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 31:2788–2793PubMedCrossRefGoogle Scholar
  48. 48.
    Hermans PW, Hibberd ML, Booy R, et al (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354: 556–560PubMedCrossRefGoogle Scholar
  49. 49.
    Westendorp RG, Hottenga JJ, Slagboom PE (1999) Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354: 561–563PubMedCrossRefGoogle Scholar
  50. 50.
    Geishofer G, Binder A, Muller M, et al (2005) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164: 486–490PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media Inc. 2008

Authors and Affiliations

  • J. -J. Hofstra
    • 1
  • M. Schouten
    • 1
  • M. Levi
    • 1
  1. 1.Department of MedicineAcademic Medical CenterAZ AmsterdamNetherlands

Personalised recommendations